Skip to content

Paul B. Beeson K76 Guide 2026: Eligibility

Updated 6 official sources

Quick Answer: The Paul B. Beeson K76 is open now. NIA posted PAR-27-112 (opens in a new tab) (K76 Clinical Trial Not Allowed) on Sept.

Full answer and how we checked it

1, 2026, and it runs through June 12, 2028. It's best if you're an early-stage clinician-scientist whose research sits clearly inside aging or geriatrics and who can show a leadership path beyond a normal mentored K award. If the project is only loosely tied to older adults, or if the candidate is still building a basic mentored record, compare K08, K23, K99/R00, R01, and foundation aging awards before writing.

Who this is for: Faculty investigators, department chairs, research development offices, and aging-research mentors deciding whether the Beeson K76 is the right route before a team spends proposal time.

Data note: This guide uses NIH K-series guidance, NIA Beeson K76 notices, the PAR-27-112 record on Grants.gov (opens in a new tab) checked on Oct. 10, 2026, and the live Paul B. Beeson program page.

In this guide

Quick Facts

Agency
HHS
Deadline
Jun 12, 2028
Status
Open

Assistance Listing 93.866: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.866, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
10,364
Avg Award (whole listing)
$3,365,037
Median Award (whole listing)
$1,781,166
Total Funding (FY2024, whole listing)
$3.8B
YoY Funding Trend
-0.1%

Data last verified: May 18, 2026

The Beeson K76 is not just another NIH K award. The official NIH K-series pages explain career-development awards broadly, but Beeson searchers usually need a narrower decision: is this candidate already far enough along to look like an emerging leader in aging, yet still early enough to need protected career-development time?

Use this guide with the live Paul B. Beeson Emerging Leaders program page. The program page gives current status, official source links, award data, and public fit signals. This guide explains the choice between Beeson, K08, K23, K99/R00, R01, and other aging-funding routes.

For broader NIH route selection, compare NIH grants complete guide, NIH R01, R21, R03, and K awards comparison, and NIH K99/R00 pathway to independence.

Teams often make the same mistake with this award: they read "career development" and treat Beeson like a safer K08 or K23. It isn't.

3 Fit Tests for the Beeson K76

The first job is deciding whether this K76 route fits, and 3 tests settle most cases. According to PAR-27-112, posted Sept. 1, 2026, candidates must have received competitively awarded research support as a PD/PI at the faculty level, or have otherwise leveraged faculty-level support to build an independent line of research, and must show leadership in the clinical or research domain. Prior NIA Beeson notices framed the program the same way: it's built for scientists prepared to take an active leadership role in aging-linked research or health outcomes.

TestStrong Beeson signalWeak signal
Aging focusThe research question is clearly about aging, geriatrics, or older-adult outcomesAging appears only as a subgroup or future application
Candidate stageFaculty-level research support, lead-author work, and mentor depth are visibleThe record is still mostly trainee-level
Leadership planThe plan shows field-building, methods growth, or specialty-level leadershipThe plan reads like a standard mentored project

The first screen is not prestige. It is fit. A strong biomedical project can still be a poor Beeson choice if the aging thread is weak.

Aging Focus

The Beeson page should answer the question a reviewer will ask first: why should NIA treat this as aging research rather than general clinical, translational, or population-health research?

Good fit examples include:

  • age-related disease mechanisms
  • geriatrics care delivery
  • older-adult functional outcomes
  • dementia, frailty, multimorbidity, or late-life health systems research
  • aging-linked clinical or translational methods

Poor fit examples include:

  • a general disease study with older adults included only because they are common patients
  • a methods project that could apply to any adult group with no aging-specific rationale
  • a clinical trial that does not explain why older-adult biology, care patterns, or outcomes matter

Candidate Stage

Prior Beeson notices asked applicants to describe prior or current competitive research support, lead-author peer-reviewed publications, and leadership in clinical or research settings. That is a higher bar than "promising junior investigator."

If the candidate does not yet have that record, the better route may be a K08, K23, K01, K99/R00, or foundation early-career award. If the candidate already has independent funding and a clear R01 path, Beeson may no longer be the best use of proposal time.

Leadership Plan

The leadership plan should not be a thin mentoring paragraph. It should explain what the candidate will be able to lead after the award that they cannot lead now.

Strong plans often show:

  • a new method or field bridge
  • a mentor team with aging depth
  • a publication and funding path
  • clinical or research leadership roles
  • training that changes the candidate's future role

Clinical-Trial Route: Do Not Guess

Two prior notices, RFA-AG-24-014 and RFA-AG-24-015, split Beeson into independent-clinical-trial-not-allowed and clinical-trial-required versions. The current notice, PAR-27-112, is Clinical Trial Not Allowed: applicants can't lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but they may propose a research experience in a trial led by a mentor or co-mentor. Grantsights checked the PAR-27-112 record on Grants.gov (opens in a new tab) on Oct. 10, 2026, and we compared it with the two prior RFAs. No clinical-trial-required Beeson notice was posted then.

Project roleLikely route question
Candidate leads an independent trial, feasibility study, or ancillary trialNot allowed under PAR-27-112; ask NIA whether another route exists
Candidate analyzes existing clinical data or observational outcomesCheck NIH's clinical-trial definition; non-trial work fits PAR-27-112
Candidate gains research experience in a trial led by a mentor or co-mentorPermitted under PAR-27-112
No human-subject interventionFits the clinical-trial-not-allowed route

Don't reuse an old RFA-AG-24-014 application shell without checking PAR-27-112. NIH clinical-trial classification can change what sections, protections, and review points matter.

Beeson vs. K08, K23, K99/R00, and R01

Beeson isn't the right route for every aging investigator. 6 routes are worth comparing before you commit. Applicants often compare Beeson against better-known NIH mechanisms, and the right answer depends on applicant stage and project center of gravity.

RouteBest fitMain reason to choose it over Beeson
Beeson K76Early-stage faculty leader in aging researchAging leadership is the core case
K08Clinician-scientist with mentored research training needsTranslational or basic clinical-science training is the main gap
K23Patient-oriented clinician-scientistDirect patient-oriented research is central
K99/R00Postdoc moving to independenceCandidate is not yet in a stable faculty route
R01Independent research projectCandidate and project no longer need career-development framing
Foundation aging awardNarrow aging mission, smaller scope, or bridge pathFunder mission fits better than NIH timing

For the live award record, use the Beeson K76 program page. For broader NIH planning, use NIH grants complete guide.

What NIH Doesn't Tell You

4 gaps matter here. NIH tells you the rules, but it does not rank your route choices, test the candidate's readiness, or tell you whether the proposal is drifting into a weaker mechanism.

First, the official notice cannot tell you whether the candidate's aging rationale is strong enough. Otherwise strong drafts sometimes have good science but mention aging only in the significance section. That is a weak Beeson posture. The aging question should shape aims, measures, cohort logic, mentor selection, and career plan.

Second, the official notice does not compare Beeson against the candidate's actual next-best route. A clinician doing patient-oriented research may be better served by K23. A physician-scientist needing lab training may belong on K08. A postdoc still moving into faculty independence may belong on K99/R00. A faculty member ready for a research-project frame may need R01 instead.

Third, the official notice does not show whether the applicant's leadership evidence is persuasive enough. A committee can see the candidate's publications and prior awards, but the public page does not translate that into a practical stop/go decision for the grant team.

Fourth, the official notice doesn't put Beeson in funding context. According to USAspending.gov (opens in a new tab) data, assistance listing 93.866 had about $3.83B in FY2024 obligations. That figure covers NIA's whole extramural research portfolio, not Beeson, so it says nothing about how many Beeson awards NIA makes or how competitive the K76 is.

The common mistake is treating "eligible" as "worth applying." This trap shows up when a candidate has a strong clinical record but the aging argument depends on one paragraph. That is a red flag. A Beeson proposal that cannot explain why older-adult outcomes drive the whole project will lose points even if the investigator is impressive.

4 Real-World Beeson Scenarios

4 real scenarios show how the decision changes in practice, especially when the same investigator could plausibly choose a K award or an R-series route.

ScenarioBetter first readWhy
Geriatrician with pilot data, aging mentors, and faculty-level supportBeeson K76The leadership and aging case are central
Surgeon studying post-operative outcomes with older adults as one subgroupK08, K23, or R01Aging may not be the main scientific frame
Postdoc with strong aging publications but no faculty appointmentK99/R00 or foundation routeBeeson usually expects a faculty-stage record
Established aging investigator with independent fundingR01 or program project routeCareer-development framing may be too late

Example 1: a geriatrician studying fall-risk interventions after hospital discharge can make a strong Beeson case if the plan connects older-adult outcomes, mentor depth, implementation path, and a leadership role in geriatrics research.

Example 2: a cardiology project with 30% older patients is not automatically a Beeson project. If the biology, measures, and future work are not centered on aging, the team should not force the mechanism.

Example 3: a PhD scientist with a strong aging postdoc record but no faculty appointment may be a better K99/R00 candidate. Beeson can be too advanced if the institutional role and leadership frame are not ready.

Example 4: a faculty investigator with a funded R01 application path may not need Beeson. In that case, the better question is whether the next application should be an R01, R21, P01 component, or foundation aging award.

One investigator at a university in Pennsylvania might study delirium outcomes after surgery, have an aging mentor, and hold pilot data from an older-adult cohort. That can be a Beeson conversation. One investigator at a cancer center in Texas might include older adults in a broad toxicity study without an aging-specific measure, mentor, or future leadership plan. That second case may be a K08, K23, or R01 conversation instead.

One hospital-based geriatrician in North Carolina might have 2 lead-author papers, a small foundation aging award, and a mentor team split across geriatrics, implementation science, and biostatistics. That is the kind of fact pattern where Beeson deserves serious review. A general internist with no aging mentor and no older-adult outcome in the aims shouldn't force the mechanism.

5 Beeson Draft Checks to Run First

5 draft checks can prevent a weak Beeson application from moving too far. The strongest drafts make the aging case visible before the reviewer reaches the career-development plan.

Draft checkPass signalRed flag
Specific aimsAging question appears in the aim logicOlder adults appear only in significance
Candidate recordPrior support and publications support an emerging-leader claimRecord reads like early mentored training only
Mentor planMentors cover aging science, method gap, and career pathMentor list is famous but loosely tied to the plan
Trial statusHuman-subject role matches the active noticeTeam is still debating clinical-trial classification late
Future fundingNext R01 or equivalent path is credibleFuture funding plan is generic

The downside of a forced Beeson application is opportunity cost. If the fit is weak, the team can lose an entire cycle that would have been better spent on K23, K08, K99/R00, R01, or a smaller foundation aging award. Don't let program prestige override route fit.

According to NIH's individual career-development overview, K awards usually support mentored research development with salary support and protected time. The Beeson decision is still local: candidate stage, aging center of gravity, mentor quality, and clinical-trial route.

Application Readiness Checklist

8 readiness items should be confirmed before writing:

  1. The project has a direct aging or geriatrics rationale.
  2. The candidate has faculty-level research support or a credible equivalent signal.
  3. The mentor team includes serious aging or geriatrics expertise.
  4. The leadership plan explains a future role, not just skills training.
  5. The active notice matches the project's clinical-trial status.
  6. The institution can protect the needed effort.
  7. The candidate can explain why Beeson is better than K08, K23, K99/R00, or R01.
  8. The team has checked current source links from the program page.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 10,364 Assistance Listing records | Avg: $3.4M

REAL DATA
1

University of California, Los Angeles

CA

$996.1M
2

Regents of the University of Michigan

MI

$463.4M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Frequently Asked Questions

Who is the Paul B. Beeson K76 for?

NIA's current notice, PAR-27-112, invites early-stage clinician-scientists whose work is centered on aging, geriatrics, or health outcomes for older adults and who can show research support, publications, mentors, and leadership promise.

Is the Beeson K76 a normal mentored K award?

No. It is a career-development award, but it isn't a standard K08 or K23. Unlike other mentored K awards, candidates must already have competitively awarded faculty-level PD/PI support or leveraged faculty-level support. Beeson targets emerging leaders in aging research rather than early applicants who only need basic mentored support.

Does the Beeson K76 allow clinical trials?

The current notice, PAR-27-112 (posted Sept. 1, 2026), is Clinical Trial Not Allowed. You can't lead an independent clinical trial, a feasibility study, or an ancillary trial, but you can propose a research experience in a trial led by a mentor or co-mentor. Prior cycles also had a clinical-trial-required version; none was posted on Grants.gov as of Oct. 10, 2026.

What should make an applicant pause before writing?

Pause if the aging link is thin, the candidate lacks faculty-level research support, or the plan reads like a standard mentored K rather than a leadership-development path.

What should applicants compare against Beeson?

Compare K08, K23, K99/R00, R01, institute-specific K routes, and foundation aging awards before choosing Beeson.

Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.